Literature DB >> 36004043

Coronary physiology to guide treatment of coronary artery disease in a patient with severe aortic valve stenosis: friend or foe? A case report.

Lennert Minten1, Keir McCutcheon1, Johan Bennett1, Christophe Dubois1.   

Abstract

Background: Severe aortic valve stenosis (AS) is the most frequent valve pathology in the developed world requiring intervention. Due to common factors in pathogenesis, patients with AS frequently have concomitant coronary artery disease (CAD). Determining the relative contribution of each component to the disease state is not easy as there is much overlap in complaints. Moreover, severe AS interferes with the haemodynamic assessment of intermediate coronary lesions. Case summary: In this case report we describe the presentation and management of an 84-year-old patient, with a severely degenerated aortic valve bioprosthesis and an intermediate coronary artery lesion, presenting with acute decompensated heart failure and chest pain. Initial invasive haemodynamic assessment of the coronary lesion provided challenging findings and a second catheterization and intervention was needed to free the patient from his chest pain. Discussion: Optimal assessment and treatment of CAD before valve replacement are controversial. Aortic valve stenosis on itself can lead to subendocardial ischaemia with subsequent angina pectoris. Simultaneously, AS can significantly affect coronary haemodynamics, hereby interfering with intra-coronary haemodynamic assessment of co-existing coronary lesions. Currently used coronary physiological indices are not validated in the AS population and valve replacement has variable effects on the fractional flow reserve and commonly used resting indices, such as the resting full-cycle ratio. Further research on this topic is needed and an overview of currently running studies that will advance this field significantly is provided.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Aortic valve stenosis; Case report; Coronary artery disease; Coronary physiology; Coronary revascularization; Microvascular function; Transcatheter aortic valve implantation

Year:  2022        PMID: 36004043      PMCID: PMC9395135          DOI: 10.1093/ehjcr/ytac333

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


Severe aortic valve stenosis (AS) and coronary artery disease very frequently co-exist and both give rise to dyspnoea and angina. Severe AS causes subendocardial ischaemia and interferes with the haemodynamic assessment of coronary lesions, necessitating caution in physiological indices interpretation. Transcatheter aortic valve implantation (TAVI) has significant but different effects on coronary indices: where fractional flow reserve (FFR) seems to decrease due to a blunted response to adenosine pre-TAVI, resting full-cycle ratio (RFR) stays stable in most cases.

Introduction

Aortic stenosis (AS) is the most common valve pathology in the developed world. Approximately 60% of patients with severe AS have concomitant CAD, and both pathologies can give rise to shared symptoms.[1] For many years, surgical aortic valve replacement (SAVR) was the gold standard for treating patients with severe AS. Transcatheter aortic valve implantation (TAVI) is now favoured in high surgical risk patients and even in selected low risk patients. However, coronary revascularization recommendations in patients undergoing TAVI are unclear, since randomized controlled trials are lacking.[2] We present a case of a patient with severe AS and concomitant CAD to illustrate the presentation and management of such a patient, highlighting the current diagnostic and therapeutic challenges with a focus on the use of invasive coronary physiology.

Case presentation

An 84-year-old male presented to the emergency department with sudden onset dyspnoea. He had a history of coronary artery bypass grafting of the LCX with the left internal mammal artery (LIMA) and simultaneous bioprosthetic (21 mm valve) SAVR 10 years before presentation. He also had a history of peripheral vascular disease. On admission, he was taking aspirin (1 × 80 mg/day), ramipril (1 × 2.5 mg/day), and rosuvastatin (1 × 20 mg/day). Laboratory tests showed an elevated NT-pro-BNP {3625 ng/L [normal range (NR): <738 ng/L]} and troponin-T that increased over 4 h from 0.056 to 0.183 ng/L (NR: <0.013 ng/L). The resting ECG showed no signs of ischaemia while the chest X-ray showed signs of pulmonary oedema. Treatment with diuretics was initiated with good effect. Transthoracic echocardiography showed a normal left ventricular (LV) systolic function with a significant gradient over the prosthetic aortic valve (AV) (peak 66 mmHg, mean 42 mmHg, peak velocity 4.1 m/s, AVAV area of 0.9 cm2). Subsequent coronary angiography showed a patent LIMA–LCX bypass with a moderate-to-severe stenosis in the RCA (). The patient’s clinical status improved and he was discharged with oral diuretics, appropriate heart failure, and antianginal medications. Angiographic image of the coronary stenosis. (A) The angiographic image of the right coronary artery stenosis through an left anterior oblique view. The stenosis is marked by the white arrow. (B) The angiographic image of the right coronary artery after the placement of two drug eluting stents. Several weeks later, he was admitted for further work-up. His dyspnoea was stable but he also complained of stable angina. An invasive functional assessment of the lesion in the mid-RCA was performed. The FFR was 0.84 (significant: ≤ 0.80), the RFR was 0.80 (significant: ≤0.89), the coronary flow reserve [CFR was 1.1 (normal ≥2.0) and the index of microvascular resistance (IMR) was 15 (normal <25)] (). Since there was still doubt about the ischaemic potential of the coronary stenosis, a myocardial perfusion Single Photon-Emission Computed Tomography with the use of regadenoson was performed. This showed a reversible perfusion defect of 15% in the inferior and inferolateral segments ().The case was discussed in the heart team meeting and since the valvular stenosis was deemed most important the patient was planned for a valve-in-valve TAVI without coronary revascularization. Changes in coronary haemodynamics after transcatheter aortic valve implantation. The top panel shows the angiographic view of the degenerated aortic valve and the coronary haemodynamic measurements during the valve work-up. The lower panel shows the angiographic view of the transcatheter aortic valve implantation prosthesis in the biological valve and the haemodynamic measurements of the same right coronary artery lesion 6 months after the valve procedure. AV, aortic valve; (PB-) CFR (norm), (pressure-bound) coronary flow reserve (normalized); IMR (norm), index of microvascular resistance (normalized); Pa, proximal coronary pressure; Pd, distal coronary pressure; RRR, resistive reserve ratio; TAVI, transcatheter aortic valve implantation. Non-invasive ischaemia testing. The figure shows the results of the myocardial perfusion single photon-emission computed tomography. Regadenoson was used to induce a stress response. A reversible perfusion defect of 15% can be seen in the inferior and inferolateral wall corresponding with the right coronary artery perfusion territory. On the left the perfusion defect is marked with white arrows. On the right the perfusion defect area is traced with white lines. The perfusion defect has an summed stress score of 14 and summed defect score of 6, a delta (Δ) extent of 12% and a delta (Δ) TPD of 9%. SDS, summed defect score; SPECT, single photon-emission computed tomography; SRS, summed rest score; SSS, summed stress score; TPD, total perfusion deficit score. The patient’s dyspnoea improved significantly, however, 6 months later he still complained of angina under optimal medical therapy. A new invasive functional assessment showed a significant decrease in FFR (0.72), with an increase in CFR (1.4) and a relative stable/slightly increased IMR (20) (). The RFR remained positive (0.80). The lesion was successfully treated with implantation of two drug eluting stents (). The patient reported complete resolution of angina 12 months after the PCI procedure.

Discussion

As highlighted in this case, determining the predominant cause of angina in a patient with severe AS and CAD can be challenging. It is known that AS causes a decline in CFR and subendocardial ischaemia due to ventricular hypertrophy, decreased diastolic perfusion time, increased left ventricular end-diastolic pressures, uncoupling of (AV) closure and LV relaxation, and potential microvascular dysfunction.[3,4] The FFR is the gold standard for physiological invasive assessment of coronary lesions, but has not been validated in patients with heart failure or AS. We report a case demonstrating discrepancy between non-invasive ischaemia testing and resting and hyperaemic invasive indices This is most likely caused by the standard FFR cut-off (0.80) not being valid in our patient with severe AS. With the administration of adenosine, the Pd/Pa (0.86) only dropped to an FFR of 0.84. This small decrease was probably caused by a blunted effect of adenosine to increase coronary flow in AS patients whom are already vasodilated at rest to avoid subendocardial ischaemia caused by the combination of the severe valve stenosis, a hypertrophic myocardium with increased cardiac work and potential microvascular dysfunction. The pressure loss over a coronary lesion increases simultaneous with the maximal flow over that lesion. Studies have shown that coronary flow and CFR increase as LV hypertrophy regresses over time after TAVI.[5] The severely altered CFR that improved after TAVI supports this hypothesis. The increase in coronary flow after TAVI in this case, resulted in the lower and hence appropriately positive FFR. Theoretically, this phenomenon of hyperaemic blunting is not a limitation of non-hyperaemic indices such as RFR. Proof of microvascular dysfunction was not provided by our measurements of IMR, although a vasospastic component was not investigated. These measurements are in line with a study that showed that angina in AS patients is caused by an abnormal cardiac–coronary coupling with reduced diastolic perfusion time rather than intrinsic microvascular dysfunction since AS patients had a normal minimal microvascular resistance.[6,7] The findings in our case are supported by previous studies that demonstrated a stable coronary flow in the wave-free period of diastole, and a significant increase in hyperaemic whole cycle flow which resulted in a significant decrease in FFR.[8,9] In contrary, a recent study reported that RFR values did significantly increase and FFR values remained stable at 6 months after TAVR.[10] Although this study had some limitations, it illustrated that even the resting indices, that were proposed to be more stable, can change due to a lower resting coronary flow after TAVI. An argument against the hypothesis of a lower resting coronary blood flow after TAVI, is a study that showed AS patients do have a higher myocardial workload but similar resting coronary blood flows before any valvular intervention.[6] We did not observe a change of RFR in our case, but we should be aware that in some patients the resting indices may increase, making it mainly a useful index to defer revascularization in this population (high negative predictive value). Since lower-risk and younger patients are more likely to undergo TAVI in the future, identifying and treating haemodynamically significant coronary lesions may become even more relevant. Although there may be no benefit of angiography-guided PCI in older patients,[11] there is some data to support FFR-guided PCI in patients undergoing TAVI.[12] Currently multiple trials on this topic are underway. The COMIC-AS study[13] investigates the acute and long-term effects of AV intervention on intra-coronary indices. Other trials are investigating physiology-guided PCI with CABG The TransCatheter Valve and Vessels Trial (TCW), angiography-guided PCI (FAITAVI), optimal timing of revascularization (TAVI-PCI), or medical management (NOTION-3) of CAD (). Active studies investigating coronary physiology in severe aortic stenosis CABG, coronary artery bypass grafting; CAD, coronary artery disease; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; RCT, randomized controlled trial; RFR, resting full-cycle ratio; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation. Click here for additional data file.
TimingDescription
10 years before initial emergency department (ED) presentationCoronary artery bypass grafting (CABG) of the left circumflex artery (LCX) with simultaneous bioprosthetic SAVR for severe aortic valve stenosis
Initial ED presentationPresentation with acute decompensated heart failure, TTE shows severe degenerated aortic bioprosthesis with high transvalvular gradients, angiography: no signs of acute coronary syndrome, right coronary artery (RCA) stenosis: 70%
1 month after ED presentationCoronary haemodynamic assessment of RCA lesion: fractional flow reserve (FFR) negative (0.84) and resting full-cycle ratio (RFR) positive (0.80)
2 months after ED presentationUncomplicated TAVI
8 months after ED presentationBecause of persistent angina new coronary haemodynamic assessment of RCA lesion: FFR positive (0.72) and RFR positive (0.80). Percutaneous coronary intervention (PCI) with two drug eluting stents
10 months after ED presentationOutpatient cardiology clinic visit: resolution of angina
20 months after ED presentation, 12 months after PCIOutpatient cardiology clinic visit: still free from angina
Table 1

Active studies investigating coronary physiology in severe aortic stenosis

StudyDescriptionParticipantsPrimary outcomeCompletion date
COMIC-AS (15) (NCT04420325)Two-centre observational study in patients with severe AS and CAD100Change in FFR and RFR and correlation with myocardial perfusion imaging2023
TCW (NCT03424941)Multicentre RCT in patients with AS and multivessel CAD328Clinical outcomes 1 year after SAVR + CABG vs. FFR-guided PCR + TAVI2023
FAITAVI (NCT03360591)Single centre RCT in patients with AS and CAD320Clinical outcomes 1 year after pre-TAVI angiography vs. physiology-guided PCI2024
NOTION-3 (NCT03058627)Multicentre RCT in patients with AS and significant CAD452Clinical outcomes 1 year after TAVI alone vs. FFR-guided PCI + TAVI2027
TAVI-PCI (NCT04310046)Multicentre RCT in patients with AS undergoing TAVI and PCI986Clinical outcomes 1 year after iFR guided PCI before vs. after TAVI2028

CABG, coronary artery bypass grafting; CAD, coronary artery disease; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; RCT, randomized controlled trial; RFR, resting full-cycle ratio; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

  13 in total

1.  Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry.

Authors:  Thomas Walther; Christian W Hamm; Gerhard Schuler; Alexander Berkowitsch; Joachim Kötting; Norman Mangner; Harald Mudra; Andreas Beckmann; Jochen Cremer; Armin Welz; Rüdiger Lange; Karl-Heinz Kuck; Friedrich W Mohr; Helge Möllmann
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

2.  Cardiac Microvascular Endothelial Cells in Pressure Overload-Induced Heart Disease.

Authors:  Sander Trenson; Hadewich Hermans; Sander Craps; Peter Pokreisz; Pauline de Zeeuw; Jore Van Wauwe; Hilde Gillijns; Denise Veltman; Fangfei Wei; Ellen Caluwé; Rik Gijsbers; Pieter Baatsen; Jan A Staessen; Bart Ghesquiere; Peter Carmeliet; Filip Rega; Bart Meuris; Bart Meyns; Wouter Oosterlinck; Jürgen Duchenne; Kaatje Goetschalckx; Jens-Uwe Voigt; Marie-Christine Herregods; Paul Herijgers; Aernout Luttun; Stefan Janssens
Journal:  Circ Heart Fail       Date:  2021-01-19       Impact factor: 8.790

3.  Long-Term Changes in Invasive Physiological Pressure Indices of Stenosis Severity Following Transcatheter Aortic Valve Implantation.

Authors:  Muhammad Sabbah; Francis R Joshi; Mikko Minkkinen; Lene Holmvang; Hans-Henrik Tilsted; Frants Pedersen; Kiril Ahtarovski; Rikke Sørensen; Niels Thue Olsen; Lars Søndergaard; Ole De Backer; Thomas Engstrøm; Jacob Lønborg
Journal:  Circ Cardiovasc Interv       Date:  2021-11-23       Impact factor: 6.546

4.  The coronary and microcirculatory measurements in patients with aortic valve stenosis study: rationale and design.

Authors:  Lennert Minten; Keir McCutcheon; Sander Jentjens; Maarten Vanhaverbeke; Vincent F M Segers; Johan Bennett; Christophe Dubois
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-22       Impact factor: 4.733

5.  2021 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Alec Vahanian; Friedhelm Beyersdorf; Fabien Praz; Milan Milojevic; Stephan Baldus; Johann Bauersachs; Davide Capodanno; Lenard Conradi; Michele De Bonis; Ruggero De Paulis; Victoria Delgado; Nick Freemantle; Martine Gilard; Kristina H Haugaa; Anders Jeppsson; Peter Jüni; Luc Pierard; Bernard D Prendergast; J Rafael Sádaba; Christophe Tribouilloy; Wojtek Wojakowski
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 35.855

6.  Left ventricular afterload reduction by transcatheter aortic valve implantation in severe aortic stenosis and its prompt effects on comprehensive coronary haemodynamics.

Authors:  Michael Stoller; Steffen Gloekler; Rainer Zbinden; David Tueller; Franz Eberli; Stephan Windecker; Peter Wenaweser; Christian Seiler
Journal:  EuroIntervention       Date:  2018-06-20       Impact factor: 6.534

7.  Transcatheter Replacement of Stenotic Aortic Valve Normalizes Cardiac-Coronary Interaction by Restoration of Systolic Coronary Flow Dynamics as Assessed by Wave Intensity Analysis.

Authors:  M Cristina Rolandi; Esther M A Wiegerinck; Lorena Casadonte; Ze-Yie Yong; Karel T Koch; Marije Vis; Jan J Piek; Jan Baan; Jos A E Spaan; Maria Siebes
Journal:  Circ Cardiovasc Interv       Date:  2016-04       Impact factor: 6.546

8.  Coronary Physiology During Exercise and Vasodilation in the Healthy Heart and in Severe Aortic Stenosis.

Authors:  Matthew Lumley; Rupert Williams; Kaleab N Asrress; Satpal Arri; Natalia Briceno; Howard Ellis; Ronak Rajani; Maria Siebes; Jan J Piek; Brian Clapp; Simon R Redwood; Michael S Marber; John B Chambers; Divaka Perera
Journal:  J Am Coll Cardiol       Date:  2016-08-16       Impact factor: 24.094

9.  Coronary Hemodynamics in Patients With Severe Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement: Implications for Clinical Indices of Coronary Stenosis Severity.

Authors:  Yousif Ahmad; Matthias Götberg; Christopher Cook; James P Howard; Iqbal Malik; Ghada Mikhail; Angela Frame; Ricardo Petraco; Christopher Rajkumar; Ozan Demir; Juan F Iglesias; Ravinay Bhindi; Sasha Koul; Nearchos Hadjiloizou; Robert Gerber; Punit Ramrakha; Neil Ruparelia; Nilesh Sutaria; Gajen Kanaganayagam; Ben Ariff; Michael Fertleman; Jon Anderson; Andrew Chukwuemeka; Darrel Francis; Jamil Mayet; Patrick Serruys; Justin Davies; Sayan Sen
Journal:  JACC Cardiovasc Interv       Date:  2018-08-25       Impact factor: 11.195

10.  Physiological Versus Angiographic Guidance for Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation.

Authors:  Mattia Lunardi; Roberto Scarsini; Gabriele Venturi; Gabriele Pesarini; Michele Pighi; Andrea Gratta; Leonardo Gottin; Marco Barbierato; Francesco Caprioglio; Anna Piccoli; Valeria Ferrero; Flavio Ribichini
Journal:  J Am Heart Assoc       Date:  2019-11-13       Impact factor: 5.501

View more
  1 in total

1.  Hyperaemic and non-hyperaemic indices for functional assessment of coronary lesions in patients with severe aortic valve stenosis.

Authors:  Andreas S Triantafyllis; Nikolaos P E Kadoglou
Journal:  Eur Heart J Case Rep       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.